Skip to main content

Advertisement

Log in

New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent

  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Any approach applied to drug discovery and development by the medical community and pharmaceutical industry has a direct impact on the future availability of improved, novel, and curative therapies for patients with cancer. By definition, drug discovery is a complex learning process whereby research efforts are directed toward uncovering and assimilating new knowledge to create and develop a drug for the purpose of providing benefit to a defined patient population. Accordingly, a highly desirable technology or approach to drug discovery should facilitate both effective learning and the application of newly discovered observations that can be exploited for therapeutic benefit. However, some believe that drug discovery is largely accomplished by serendipity and therefore appropriately addressed by screening a large number of compounds. Clearly, this approach has not generated an abundance of new drugs for cancer patients and suggests that a tangibly different approach in drug discovery is warranted. We employ an alternative approach to drug discovery, which is based on the elucidation and exploitation of biological, pharmacological, and biochemical mechanisms that have not been previously recognized or fully understood. Mechanism-based drug discovery involves the combined application of physics-based computer simulations and laboratory experimentation. There is increasing evidence that agreement between simulations based on the laws of physics and experimental observations results in a higher probability that such observations are more accurate and better understood as compared with either approach used alone. Physics-based computer simulation applied to drug discovery is now considered by experts in the field to be one of the ultimate methodologies for drug discovery. However, the ability to perform truly comprehensive physics-based molecular simulations remains limited by several factors, including the enormous computer-processing power that is required to perform the formidable mathematical operations and data processing (e.g. memory bandwidth, data storage and retrieval). Another major consideration is the development of software that can generate an appropriate and increasingly complex physical representation of the atomic arrangements of biological systems. During the past 17 years, we have made tremendous progress in addressing some of these obstacles by developing and optimizing physics-based computer programs for the purpose of obtaining increasingly accurate and precise information and by improving the speed of computation. To perform physics-based simulations that involve complex systems of biological and pharmaceutical interest, we have developed methods that enable us to exceed Moore's law. This has been accomplished by parallel processing as well as other methods that have enabled us to study more complex and relevant molecular systems of interest. This paper provides an overview of our approach to drug discovery and describes a novel drug, currently in clinical development, which has directly resulted from the application of this approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1A, B.
Fig. 2.
Fig. 3.
Fig. 4.

Similar content being viewed by others

References

  1. Anderson PJ (1979) The structure and amount of tubulin in cells and tissues. J Biol Chem 254:2168

    CAS  PubMed  Google Scholar 

  2. Brock N, Pohl J, Stekar J, Scheef W (1982) Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 18:1377

    CAS  PubMed  Google Scholar 

  3. Cavalletti E, Cavaletti G, Tredici G, Oggioni N, Spinelli S, Reddy D, Parker A, Yao S, Zhao M, Wu M, Hausheer F (1999) Oral and intravenous BNP7787 protects against paclitaxel-mediated neurotoxicity in Wistar rats (abstract 2632). Proc Am Assoc Cancer Res

  4. Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1996) Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 62:166

    Google Scholar 

  5. Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. Am J Physiol 257:L163

    CAS  PubMed  Google Scholar 

  6. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff VA (1948) Temporary remissions in acute leukemia in children produced by folic antagonist 4-amethopteroylglutamic acid (aminopterin). N Engl J Med 238:787

    CAS  Google Scholar 

  7. Fleming A (1929) On the antibacterial action of culture of a penicillium, with special reference to their use in the isolation of B. influenza. Br J Exp Pathol 10:226

    CAS  Google Scholar 

  8. Gilbert HF (1990) Molecular and cellular aspects of thiol–disulfide exchange. Adv Enzymol Relat Areas Mol Biol 63:69

    CAS  PubMed  Google Scholar 

  9. Gilbert HF (1995) Thiol/disulfide exchange equilibria and disulfide bond stability. Methods Enzymol 251:8

    CAS  PubMed  Google Scholar 

  10. Gilman A (1963) The initial clinical trial of nitrogen mustard. Am J Surg 105:574

    CAS  Google Scholar 

  11. Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM (1998) Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin Oncol 25:584

    Google Scholar 

  12. Hausheer F, Kochat H, Reddy D, Zhao M, Seetharamulu P, Yao S, Pavankumar P, Murali D, Wu M, Saxe J, Parker A, Hamilton S, Huang Q, Chen X, Berghorn E (2000) BNP7787: a novel chemoprotecting agent for platinum and taxane toxicity (abstract 4890). Proc Am Assoc Cancer Res

  13. Hausheer F, Kochat H, Zhao A, Hamilton S, Wu M, Seetharamulu P, Petluru P, Yao S, Huang Q, Chen X, Ma H, Ding D, Leverett B, Wu Y, Wang J, Saxe J, Parker A, Berghorn E (2001) BNP7787, a novel neuroprotective agent in taxane and platinum regimens, does not interfere with chemotherapeutic effects (abstract 1990). Proc Am Assoc Cancer Res

  14. Heidelberger C, Chaudhuri NK, Danenberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J (1957) Fluorinated pyrimidines: a new class of antitumor compounds. Nature 179:663

    CAS  Google Scholar 

  15. Kleinman WA, Richie JP (2000) Status of glutathione and other thiols and disulfides in human plasma. Biochem Pharmacol 60:19

    Article  CAS  PubMed  Google Scholar 

  16. Pavankumar PNV, Seetharamulu S, Yao S, Saxe JD, Dasharatha GR, Hausheer FH (1999) Comprehensive ab initio quantum mechanical and molecular orbital (MO) analysis of cisplatin: structure, bonding, charge density, and vibrational frequencies. J Comput Chem 20:365

    Article  CAS  Google Scholar 

  17. Pharmaceutical Research and Manufacturers of America (PhRMA) Annual Report 2001–2002, p 13

  18. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G (2002) Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539

    Article  CAS  PubMed  Google Scholar 

  19. Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55:2303

    CAS  PubMed  Google Scholar 

  20. Rosenberg B, Van Camp L, Grimley EB, Thomson AJ (1967) The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. J Biol Chem 242:1347

    CAS  PubMed  Google Scholar 

  21. Schafer FQ, Buettner G (2001) Redox enviroment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191

    Article  CAS  PubMed  Google Scholar 

  22. Schiff PB, Horwitz SB (1981) Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule associated proteins. Biochemistry 20:3247

    CAS  PubMed  Google Scholar 

  23. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665

    CAS  PubMed  Google Scholar 

  24. Stein AF, Dills RL, Klaasen CD (1986) High-performance liquid chromatographic analysis of glutathione and its thiol and disulfide degradation products. J Chromatogr 381:259

    Article  CAS  PubMed  Google Scholar 

  25. Tufts Center for the Study of Drug Development (2003) Impact Report: Post-approval R&D raises total drug development costs to US$ 800 million. Vol. 5, No. 3, May/June 2003, http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=4

  26. Verschraagen M, Boven E, Ruijter R, van der Born K, Berkhof J, Hausheer FH, van der Vijgh WJF (2003) Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clin Pharmacol Ther (in press)

  27. Wall ME, Wani MC (1995) Camptothecin and taxol: discovery to clinic. Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55:753

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frederick H. Hausheer.

Additional information

This work was presented at the 18th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium, "New Strategies for Novel Anticancer Drug Development", 8–9 November 2002, Nagoya, Japan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hausheer, F.H., Kochat, H., Parker, A.R. et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol 52 (Suppl 1), 3–15 (2003). https://doi.org/10.1007/s00280-003-0653-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0653-5

Keywords

Navigation